Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)
Conditions
- Renal Cell Carcinoma
- Papillary Renal Cell Carcinoma Type 1
- Papillary Renal Cell Carcinoma Type 2
- Chromophobe Renal Cell Carcinoma
- Sarcomatoid Renal Cell Carcinoma
- Xp11 Translocation Carcinoma
Interventions
- DRUG: Nivolumab
- DRUG: Ipilimumab
Sponsor
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Collaborators